Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27455671 | 0.85 | TDP1 (0.60) | ATMTDP1PDE7AVCAM1HSPB1 | |
| SCHEMBL404745 | 0.83 | VCAM1 (0.64) | ATMTDP1PDE7AVCAM1HSPB1 | |
| SCHEMBL1795352 | 0.78 | TDP1 (0.57) | TDP1VCAM1HSPB1ALDH1A1HIF1A | |
| SCHEMBL7734099 | 0.78 | VCAM1 (0.44) | ATMTDP1VCAM1ALDH1A1MAPT | |
| SCHEMBL29745239 | 0.77 | TDP1 (0.72) | ATMTDP1PDE7AVCAM1HSPB1 | |
| SCHEMBL216553 | 0.77 | TDP1 (0.72) | ATMTDP1PDE7AVCAM1HSPB1 | |
| SCHEMBL7664972 | 0.77 | VCAM1 (0.71) | TDP1PDE7AVCAM1ALDH1A1MAPK1 | |
| SCHEMBL8762851 | 0.77 | ALDH1A1 (0.51) | TDP1ALDH1A1HIF1AMAPTMAPK1 | |
| SCHEMBL1019385 | 0.77 | TDP1 (0.50) | ATMTDP1PDE7AVCAM1HSPB1 | |
| SCHEMBL28623382 | 0.76 | ATM (0.46) | ATMTDP1PDE7AVCAM1HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100034748-A1 | Molecular imaging probes based on loaded reactive nano-scale latex | QUANTUM MEDICAL HOLDINGS, LLC | 2010-02-11 | — | — | US | claimed |
| WO-2010016858-A2 | MOLECULAR IMAGING PROBES | CARESTREAM HEALTH, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| US-20100034748-A1 | Molecular imaging probes based on loaded reactive nano-scale latex | QUANTUM MEDICAL HOLDINGS, LLC | 2010-02-11 | — | — | US | disclosed |
| WO-2010016858-A2 | MOLECULAR IMAGING PROBES | CARESTREAM HEALTH, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034748-A1 | Molecular imaging probes based on loaded reactive nano-scale latex | CLTA, COPE, CD68 | ATM 1350/4885TDP1 987/4885PDE7A 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.